

Francesco Prattichizzo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3812584/francesco-prattichizzo-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77
papers

2,493
citations

31
h-index

48
g-index

82
ext. papers

3,378
ext. citations

8
avg. IF

5.75
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 77 | HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 13 | 8.7 | 1 |
| 76 | Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms.. <i>Journal of Clinical Medicine</i> , 2022 , 11, | 5.1 | 4 |
| 75 | Senescent macrophages in the human adipose tissue as a source of inflammaging.. <i>GeroScience</i> , 2022 , 1 | 8.9 | 2 |
| 74 | Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes.. <i>Nature Communications</i> , 2022 , 13, 2318 | 17.4 | 4 |
| 73 | Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.. <i>Cellular and Molecular Life Sciences</i> , 2022 , 79, 273 | 10.3 | 2 |
| 72 | Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. <i>Cardiovascular Diabetology</i> , 2021 , 20, 218 | 8.7 | 7 |
| 71 | Glycaemic management in diabetes: old and new approaches. <i>Lancet Diabetes and Endocrinology</i> , 2021 , | 18.1 | 9 |
| 70 | CD4 T-Cell Activation Prompts Suppressive Function by Extracellular Vesicle-Associated MicroRNAs. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 753884 | 5.7 | 2 |
| 69 | Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 138-139 | 18.1 | 3 |
| 68 | The pleiotropic roles of leptin in metabolism, immunity, and cancer. <i>Journal of Experimental Medicine</i> , 2021 , 218, | 16.6 | 10 |
| 67 | Tackling the pillars of ageing to fight COVID-19. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e191 | 9.5 | 4 |
| 66 | DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021 , 14, 1519-1531 | 3.4 | 5 |
| 65 | Variability of risk factors and diabetes complications. <i>Cardiovascular Diabetology</i> , 2021 , 20, 101 | 8.7 | 5 |
| 64 | Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: A sistematic review and meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , e3476 | 7.5 | 9 |
| 63 | Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. <i>Immunity</i> , 2021 , 54, 1543-1560.e6 | 32.3 | 7 |
| 62 | Pharmacological management of COVID-19 in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107927 | 3.2 | 7 |
| 61 | Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. <i>Metabolism: Clinical and Experimental</i> , 2021 , 120, 154799 | 12.7 | 9 |

| | | | |
|----|---|------|----|
| 60 | Response to: Letter to the Editor on "Bonafini M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev" by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella. <i>Cytokine and Growth Factor Reviews</i> , 2021 , 58, 141-143 | 17.9 | 7 |
| 59 | T Cells: Warriors of SARS-CoV-2 Infection. <i>Trends in Immunology</i> , 2021 , 42, 18-30 | 14.4 | 65 |
| 58 | CD31 Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated With Cardiovascular Complications. <i>Diabetes</i> , 2021 , 70, 240-254 | 0.9 | 19 |
| 57 | Effect of time and titer in convalescent plasma therapy for COVID-19. <i>iScience</i> , 2021 , 24, 102898 | 6.1 | 8 |
| 56 | Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register. <i>Cardiovascular Diabetology</i> , 2021 , 20, 173 | 8.7 | 4 |
| 55 | miR-21 and miR-146a: The microRNAs of inflammaging and age-related diseases. <i>Ageing Research Reviews</i> , 2021 , 70, 101374 | 12 | 30 |
| 54 | Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications. <i>Theranostics</i> , 2021 , 11, 1031-1045 | 12.1 | 20 |
| 53 | Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. <i>Cytokine and Growth Factor Reviews</i> , 2020 , 53, 33-37 | 17.9 | 84 |
| 52 | Circulating MicroRNA-15a Associates With Retinal Damage in Patients With Early Stage Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2020 , 11, 254 | 5.7 | 5 |
| 51 | Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1696-1700 | 6.7 | 25 |
| 50 | Why is hyperglycaemia worsening COVID-19 and its prognosis?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1951-1952 | 6.7 | 46 |
| 49 | The beneficial effects (on cardio-renal system) of glucose-lowering agents with caloric-restriction mimetic properties are subtractive rather than additive. <i>Diabetes Research and Clinical Practice</i> , 2020 , 163, 108030 | 7.4 | |
| 48 | Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios. <i>Metabolism: Clinical and Experimental</i> , 2020 , 110, 154308 | 12.7 | 19 |
| 47 | Small extracellular vesicles deliver miR-21 and miR-217 as pro-senescence effectors to endothelial cells. <i>Journal of Extracellular Vesicles</i> , 2020 , 9, 1725285 | 16.4 | 63 |
| 46 | Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 15 |
| 45 | Pleiotropic effects of polyphenols on glucose and lipid metabolism: Focus on clinical trials. <i>Ageing Research Reviews</i> , 2020 , 61, 101074 | 12 | 14 |
| 44 | Two drugs are better than one to start T2DM therapy. <i>Nature Reviews Endocrinology</i> , 2020 , 16, 15-16 | 15.2 | 9 |
| 43 | Plasma circulating miR-23~27~24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes. <i>Diabetologia</i> , 2020 , 63, 2699-2712 | 10.3 | 9 |

| | | | |
|----|---|------|-----|
| 42 | One-hour plasma glucose combined with skin autofluorescence identifies subjects with pre-diabetes: the DIAPASON study. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8, | 4.5 | 4 |
| 41 | Long-term exposure of human endothelial cells to metformin modulates miRNAs and isomiRs. <i>Scientific Reports</i> , 2020 , 10, 21782 | 4.9 | 6 |
| 40 | Ageing as a druggable process: Moving forward. <i>EBioMedicine</i> , 2019 , 40, 15-16 | 8.8 | 4 |
| 39 | NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2019 , 8, | 5.1 | 24 |
| 38 | Type 2 Diabetes: How Much of an Autoimmune Disease?. <i>Frontiers in Endocrinology</i> , 2019 , 10, 451 | 5.7 | 42 |
| 37 | Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high risk of developing diabetes and in drug-naïve T2D. <i>Cardiovascular Diabetology</i> , 2019 , 18, 18 | 8.7 | 40 |
| 36 | Inflamm-aging microRNAs may integrate signals from food and gut microbiota by modulating common signalling pathways. <i>Mechanisms of Ageing and Development</i> , 2019 , 182, 111127 | 5.6 | 12 |
| 35 | Extracellular vesicles circulating in young organisms promote healthy longevity. <i>Journal of Extracellular Vesicles</i> , 2019 , 8, 1656044 | 16.4 | 25 |
| 34 | Where Metabolism Meets Senescence: Focus on Endothelial Cells. <i>Frontiers in Physiology</i> , 2019 , 10, 15234.6 | | 56 |
| 33 | The link between diabetes and atherosclerosis. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 15-24 | 4.9 | 43 |
| 32 | Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 73-80 | 3.9 | 39 |
| 31 | MiR-146a-5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor-alpha inhibitor adalimumab. <i>British Journal of Dermatology</i> , 2018 , 179, 787-789 | 4 | 15 |
| 30 | Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages. <i>Redox Biology</i> , 2018 , 15, 170-181 | 11.3 | 69 |
| 29 | Anti-senescence compounds: A potential nutraceutical approach to healthy aging. <i>Ageing Research Reviews</i> , 2018 , 46, 14-31 | 12 | 97 |
| 28 | Inflammaging and metaflammation: The yin and yang of type 2 diabetes. <i>Ageing Research Reviews</i> , 2018 , 41, 1-17 | 12 | 117 |
| 27 | Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2515-2522 | 6.7 | 62 |
| 26 | Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability. <i>Cardiovascular Diabetology</i> , 2018 , 17, 105 | 8.7 | 47 |
| 25 | Novel insights into the regulation of miRNA transcriptional control: implications for T2D and related complications. <i>Acta Diabetologica</i> , 2018 , 55, 989-998 | 3.9 | 12 |

| | | | |
|----|---|-----|-----|
| 24 | Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions. <i>Oncotarget</i> , 2018 , 9, 8898-8910 | 3.3 | 10 |
| 23 | The mitomiR/Bcl-2 axis affects mitochondrial function and autophagic vacuole formation in senescent endothelial cells. <i>Aging</i> , 2018 , 10, 2855-2873 | 5.6 | 18 |
| 22 | Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. <i>Ageing Research Reviews</i> , 2018 , 48, 87-98 | 12 | 54 |
| 21 | The Activity of L. Essential Oil on Inflammation. <i>Journal of Medicinal Food</i> , 2018 , 21, 1238-1243 | 2.8 | 5 |
| 20 | Exosome-based immunomodulation during aging: A nano-perspective on inflamm-aging. <i>Mechanisms of Ageing and Development</i> , 2017 , 168, 44-53 | 5.6 | 51 |
| 19 | The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. <i>Endocrine</i> , 2017 , 56, 509-520 | 4 | 41 |
| 18 | The "Metabolic Memory" Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. <i>Nutrients</i> , 2017 , 9, | 6.7 | 116 |
| 17 | Mitochondrial (Dys) Function in Inflammaging: Do MitomiRs Influence the Energetic, Oxidative, and Inflammatory Status of Senescent Cells?. <i>Mediators of Inflammation</i> , 2017 , 2017, 2309034 | 4.3 | 27 |
| 16 | Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM. <i>Oncotarget</i> , 2017 , 8, 93338-93348 | 3.3 | 13 |
| 15 | Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 855-67 | 6.7 | 46 |
| 14 | Chemical composition and In vitro In vitro anti-inflammatory activity of <i>Vitis vinifera</i> L. (var. Sangiovese) tendrils extract. <i>Journal of Functional Foods</i> , 2016 , 20, 291-302 | 5.1 | 13 |
| 13 | Senescence associated macrophages and "macroph-aging": are they pieces of the same puzzle?. <i>Aging</i> , 2016 , 8, 3159-3160 | 5.6 | 36 |
| 12 | Leukocyte telomere length and mortality risk in patients with type 2 diabetes. <i>Oncotarget</i> , 2016 , 7, 50835-50844 | 3.3 | 55 |
| 11 | Anti-TNF- α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. <i>Oncotarget</i> , 2016 , 7, 11945-58 | 3.3 | 57 |
| 10 | Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools. <i>Current Drug Targets</i> , 2016 , 17, 388-97 | 3 | 20 |
| 9 | "Inflammaging" as a Druggable Target: A Senescence-Associated Secretory Phenotype-Centered View of Type 2 Diabetes. <i>Oxidative Medicine and Cellular Longevity</i> , 2016 , 2016, 1810327 | 6.7 | 68 |
| 8 | Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. <i>Clinical Epigenetics</i> , 2015 , 7, 56 | 7.7 | 64 |
| 7 | MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. <i>Oncotarget</i> , 2015 , 6, 35372-82 | 3.3 | 79 |

| | | | |
|---|---|-----|-----|
| 6 | MitomiRs in human inflamm-aging: a hypothesis involving miR-181a, miR-34a and miR-146a. <i>Experimental Gerontology</i> , 2014 , 56, 154-63 | 4.5 | 145 |
| 5 | Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. <i>Aging</i> , 2014 , 6, 771-87 | 5.6 | 78 |
| 4 | Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy--a study with monozygotic twin pairs. <i>Mechanisms of Ageing and Development</i> , 2014 , 143-144, 1-8 | 5.6 | 35 |
| 3 | Toll like receptor signaling in "inflammaging": microRNA as new players. <i>Immunity and Ageing</i> , 2013 , 10, 11 | 9.7 | 101 |
| 2 | Anti-inflammatory effect of ubiquinol-10 on young and senescent endothelial cells via miR-146a modulation. <i>Free Radical Biology and Medicine</i> , 2013 , 63, 410-20 | 7.8 | 56 |
| 1 | Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes. <i>Cell Death and Disease</i> , 2013 , 4, e594 | 9.8 | 16 |